The role of cytokines in the immune response to tuberculosis.

[1]  G. Kaplan,et al.  Effect of rhuIFN-gamma treatment in multibacillary leprosy patients. , 1996, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[2]  R. North,et al.  Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice , 1995, Infection and immunity.

[3]  B. Johnson,et al.  Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. , 1995, Cytokines and molecular therapy.

[4]  W. Boom,et al.  Alveolar macrophages as accessory cells for human gamma delta T cells activated by Mycobacterium tuberculosis. , 1995, Journal of immunology.

[5]  B. Zwilling,et al.  Growth of Mycobacterium tuberculosis in BCG-resistant and -susceptible mice: establishment of latency and reactivation , 1995, Infection and immunity.

[6]  W. Rom,et al.  Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis , 1995, Molecular medicine.

[7]  D. Kunimoto,et al.  Secretion of human interleukin 2 by recombinant Mycobacterium bovis BCG , 1995, Infection and immunity.

[8]  A. Gottlieb,et al.  GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo. , 1994, The Journal of investigative dermatology.

[9]  R. Wallis,et al.  Cytokines and tuberculosis , 1994, Journal of leukocyte biology.

[10]  I. Orme,et al.  Disseminated tuberculosis in interferon gamma gene-disrupted mice , 1993, The Journal of experimental medicine.

[11]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[12]  W. Rom,et al.  Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. , 1993, The Journal of infectious diseases.

[13]  J. Abrams,et al.  Cytokine production at the site of disease in human tuberculosis , 1993, Infection and immunity.

[14]  G. Kaplan,et al.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.

[15]  I. Orme,et al.  T cell response to Mycobacterium tuberculosis. , 1993, The Journal of infectious diseases.

[16]  T. Lee,et al.  Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components. , 1993, The Journal of clinical investigation.

[17]  T. Hada,et al.  Local production and localization of transforming growth factor‐beta in tuberculous pleurisy , 1993, Clinical and experimental immunology.

[18]  G. Kaplan,et al.  Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. , 1993, The Journal of infectious diseases.

[19]  J. Ellner,et al.  Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma delta T cells activated by live Mycobacterium tuberculosis , 1992, Infection and immunity.

[20]  Christopher J. L. Murray,et al.  Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.

[21]  K. Tracey,et al.  Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. , 1992, The American journal of tropical medicine and hygiene.

[22]  G. Kaplan,et al.  Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients , 1992, The Journal of experimental medicine.

[23]  G. Kaplan,et al.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing , 1992, The Journal of experimental medicine.

[24]  Kendall A. Smith,et al.  Rational Immunotherapy with Interleukin 2 , 1992, Bio/Technology.

[25]  M. Denis.  Involvement of Cytokines in Determining Resistance and Acquired Immunity in Murine Tuberculosis , 1991, Journal of leukocyte biology.

[26]  T. Ogawa,et al.  Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis , 1991, Infection and immunity.

[27]  G. Kaplan,et al.  The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy , 1991, The Journal of experimental medicine.

[28]  G. Kaplan,et al.  In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. , 1991, Cellular immunology.

[29]  S. Kishimoto,et al.  Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis , 1990, Infection and immunity.

[30]  G. Kaplan,et al.  Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Kaplan,et al.  Intradermal Recombinant Interleukin 2 Enhances Peripheral Blood T‐Cell Responses to Mitogen and Antigens in Patients with Lepromatous Leprosy , 1990, Scandinavian journal of immunology.

[32]  P. Brennan,et al.  Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. , 1990, Journal of immunology.

[33]  J. Ellner,et al.  Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Kaplan,et al.  Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis. , 1990, The Journal of infectious diseases.

[35]  G. Schuler,et al.  Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation , 1990, The Journal of experimental medicine.

[36]  E. A. Havell.  Evidence that tumor necrosis factor has an important role in antibacterial resistance. , 1989, Journal of immunology.

[37]  L. Bermudez,et al.  Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. , 1989, Journal of immunology.

[38]  G. Rook,et al.  Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. , 1989, Clinical and experimental immunology.

[39]  V. Kindler,et al.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection , 1989, Cell.

[40]  G. Kaplan,et al.  The generation of antigen-specific, major histocompatibility complex- restricted cytotoxic T lymphocytes of the CD4+ phenotype. Enhancement by the cutaneous administration of interleukin 2 , 1989, The Journal of experimental medicine.

[41]  G. Kaplan,et al.  The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2 , 1989, The Journal of experimental medicine.

[42]  J. Ellner,et al.  Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens , 1988, Infection and immunity.

[43]  G. Kaplan,et al.  Keratinocyte growth regulation by the products of immune cells , 1988, The Journal of experimental medicine.

[44]  G. Asherson,et al.  Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice , 1988, Infection and immunity.

[45]  R. Steinman,et al.  Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells , 1987, The Journal of experimental medicine.

[46]  S. Kaufmann,et al.  Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. , 1987, Journal of immunology.

[47]  G. Kaplan,et al.  Distribution and turnover of Langerhans cells during delayed immune responses in human skin , 1987, The Journal of experimental medicine.

[48]  Z. Toossi,et al.  Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis , 1986, The Journal of experimental medicine.

[49]  R. Steinman,et al.  Influence of delayed immune reactions on human epidermal keratinocytes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. J. Crowle,et al.  Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria , 1985, Infection and immunity.

[51]  G. Kinasewitz,et al.  Mycobacterial, fungal, actinomycotic, and nocardial infections of the pleura. , 1985, Clinics in chest medicine.

[52]  B. Luft,et al.  Effect of murine interferon gamma on murine toxoplasmosis. , 1984, The Journal of infectious diseases.

[53]  H. Murray,et al.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. , 1983, The Journal of clinical investigation.

[54]  A M Dannenberg,et al.  Pathogenesis of pulmonary tuberculosis. , 1982, The American review of respiratory disease.

[55]  G. Kaplan,et al.  Recombinant cytokines for controlling mycobacterial infections. , 1995, Trends in microbiology.

[56]  P. Fine,et al.  The BCG Experience: Implications for Future Vaccines against Tuberculosis , 1994 .

[57]  I. Orme,et al.  Mouse Model of Tuberculosis , 1994 .

[58]  J. Ellner,et al.  T-Cell Responses and Cytokines , 1994 .

[59]  G. Kaplan,et al.  TNFα regulation of HIV1: biology and therapy , 1994 .

[60]  B. Bloom,et al.  Tuberculosis Pathogenesis, Protection, and Control , 1994 .

[61]  B. Beutler,et al.  The common mediator of shock, cachexia, and tumor necrosis. , 1988, Advances in immunology.